Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | QPCT | Q16769 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.37 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CFTR | P13569 | 1/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10902022 | 0.76 | RAB9A (0.50) | ESR1ESR2GSK3BHIF1AMAOB | |
| SCHEMBL10899785 | 0.73 | MAPK14 (0.49) | ESR1ESR2GSK3BQPCTHIF1A | |
| SCHEMBL6636523 | 0.73 | ADRA2A (0.59) | ESR1ESR2MAOBADRA2AADRA2B | |
| SCHEMBL10901534 | 0.73 | MAOB (0.70) | ESR1ESR2HIF1AMAOBAPP | |
| Lithium Ion SCHEMBL6636809 | 0.72 | ESR1 (0.41) | ESR1ESR2GSK3BQPCTHIF1A | |
| SCHEMBL692648 | 0.71 | DYRK1A (0.44) | CA1CA2CA9 | |
| SCHEMBL2331077 | 0.71 | MAPT (0.52) | CA1CA2CA9 | |
| Pyridarone SCHEMBL29993452 | 0.71 | MAOB (0.62) | CA1CA2CA9MAOBADRA2A | |
| Pyridarone SCHEMBL2109298 | 0.71 | MAOB (0.62) | CA1CA2CA9MAOBADRA2A | |
| SCHEMBL6805707 | 0.70 | F10 (0.41) | CA1CA2CA9ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686348-B2 | N-HYDROXY-6-((2-(4-PYRIDYL)-1-BENZOFURAN-5-YL)SULPHONYL)-4,5,6,7 -TETRAHYDRO(2,3-C)-PYRIDINE-5-CARBOXAMIDE FOR EXAMPLE; TREATING RHEUMATIC DISEASES, CANCER | LES LABORATOIRES SERVIER (FR) | 2004-02-03 | — | — | US | disclosed |
| US-20020137744-A1 | Metalloprotease inhibitors | LES LABORATOIRES SERVIER (FR) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137744-A1 | Metalloprotease inhibitors | MMP9, MMP3, MMP2 | CA1 110/4885CA2 191/4885CA9 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.